Literature DB >> 3211161

Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule.

F Maillet1, M Petitou, J Choay, M D Kazatchkine.   

Abstract

Fluid phase heparin inhibits formation of the classical and alternative pathway C3 convertase of complement in assays performed either with purified complement proteins or in whole serum. Experiments using oligosaccharides of homogeneous mol. wt obtained by mild nitrous hydrolysis of heparin, demonstrated that the inhibitory activity of heparin increased exponentially with mol. wt for fragments containing between 4 and 14 saccharidic units and that fragments of mol. wt above 4700 (greater than 14 saccharidic units) had a similar anti-complementary activity to that of native heparin. Fragments of homogeneous mol. wt (octasaccharides) separated by ion exchange chromatography on the basis of negative charges, exhibited increasing inhibitory activity with increasing sulfate content. Over-sulfation of fragments of defined mol. wt resulted in a constant enhancement of the relative capacity of each fragment species to inhibit formation of the classical and alternative pathway C3 convertases. A synthetic pentasaccharide representing the minimal critical sequence responsible for the binding of heparin to anti-thrombin III exhibited a similar inhibitory capacity on formation of the C3 convertases as another synthetic pentasaccharide that was devoid of anti-Xa activity. These studies contribute to define a minimal structure of the heparin molecule with C3b- and C4b-binding capacity and definitively establish the independency of the anti-coagulant and anti-complementary sites on the heparin molecule.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3211161     DOI: 10.1016/0161-5890(88)90130-7

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  11 in total

Review 1.  Challenges and emerging technologies in the immunoisolation of cells and tissues.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  Adv Drug Deliv Rev       Date:  2007-10-11       Impact factor: 15.470

2.  Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials.

Authors:  T E Mollnes; V Videm; J Riesenfeld; P Garred; J L Svennevig; E Fosse; K Hogasen; M Harboe
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

3.  Factor h and properdin recognize different epitopes on renal tubular epithelial heparan sulfate.

Authors:  Azadeh Zaferani; Romain R Vivès; Pieter van der Pol; Gerjan J Navis; Mohamed R Daha; Cees van Kooten; Hugues Lortat-Jacob; Marc A Seelen; Jacob van den Born
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

4.  Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H.

Authors:  S Meri; M K Pangburn
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

Review 5.  Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices.

Authors:  Shang Song; Shuvo Roy
Journal:  Biotechnol Bioeng       Date:  2016-01-04       Impact factor: 4.530

6.  Thrombosis and inflammation in intraportal islet transplantation: a review of pathophysiology and emerging therapeutics.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  J Diabetes Sci Technol       Date:  2008-09

7.  Hyperglycemic conditions inhibit C3-mediated immunologic control of Staphylococcus aureus.

Authors:  Pamela S Hair; Charlene G Echague; Reuben D Rohn; Neel K Krishna; Julius O Nyalwidhe; Kenji M Cunnion
Journal:  J Transl Med       Date:  2012-03-05       Impact factor: 5.531

8.  Structural analysis and anti-complement activity of polysaccharides from Kjellmaniella crsaaifolia.

Authors:  Wenjing Zhang; Weihua Jin; Delin Sun; Luyu Zhao; Jing Wang; Delin Duan; Quanbin Zhang
Journal:  Mar Drugs       Date:  2015-03-16       Impact factor: 5.118

9.  Oversulfated chondroitin sulfate inhibits the complement classical pathway by potentiating C1 inhibitor.

Authors:  Zhao-Hua Zhou; Mohsen Rajabi; Trina Chen; Elena Karnaukhova; Steven Kozlowski
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

10.  Protective role of heparin in the injury of the liver and kidney on the experimental model of ischemia/reperfusion.

Authors:  Ali Ümit Yener; Mustafa Cüneyt Çiçek; Serhat Bahadır Genç; Turgut Özkan; Emre Doğan; Bülent Cağlar Bilgin; Tezcan Akın; Havva Erdem; Handan Ankarali
Journal:  J Cardiothorac Surg       Date:  2014-02-17       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.